Literature DB >> 12477237

Idiopathic retroperitoneal fibrosis and ankylosing spondylitis. A new case report.

A Bezza1, A El Maghraoui, M Ghadouane, F Tabache, A Abouzahir, M Abbar, D Ghafir, V Ohayon, M I Archane.   

Abstract

The case of a 52-year-old man with retroperitoneal fibrosis and ankylosing spondylitis is described. Inflammatory low back pain and acute renal insufficiency prompted a computed tomography scan of the abdomen with contrast agent injection. A fibrous sheath surrounding the aorta and attracting the ureters toward the midline was seen, strongly suggesting retroperitoneal fibrosis. The diagnosis of ankylosing spondylitis was based on the presence of inflammatory low back pain responsive to nonsteroidal anti-inflammatory drugs, syndesmophytes at the lumbar and cervical spine, bilateral sacroiliitis, and presence of the HLA-B27 antigen. Prednisone therapy in a daily dosage of 1 mg/kg induced a marked improvement. Only nine cases of concomitant retroperitoneal fibrosis and ankylosing spondylitis have been reported. These two conditions share similarities in some of the etiologic factors and anatomic localizations, suggesting that both may stem from a predisposition to fibrotic diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477237     DOI: 10.1016/s1297-319x(02)00438-4

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  3 in total

1.  Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis.

Authors:  Abdellah El Maghraoui; Saida Tellal; Souad Chaouir; Khalil Lebbar; Ahmed Bezza; Abderrazak Nouijai; Lahsen Achemlal; Sanaa Bouhssain; El Mostapha Derouiche
Journal:  Clin Rheumatol       Date:  2004-12-08       Impact factor: 2.980

2.  Mycophenolate mofetil in the treatment of retroperitoneal fibrosis.

Authors:  Fareeha Khalil; M A Mir; Rocco C Venuto
Journal:  Clin Rheumatol       Date:  2008-01-08       Impact factor: 2.980

Review 3.  Hyper-IgG4 disease: report and characterisation of a new disease.

Authors:  Guy H Neild; Manuel Rodriguez-Justo; Catherine Wall; John O Connolly
Journal:  BMC Med       Date:  2006-10-06       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.